Your browser is no longer supported. Please, upgrade your browser.
MYNZ [NASD]
Mainz Biomed B.V.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand11.71M Perf Week-43.98%
Market Cap182.09M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month49.66%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.02 Perf Half Y-
Book/sh0.11 P/B140.09 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range7.80 - 30.00 Perf YTD49.66%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.17% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low99.36% ATR2.84
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)48.43 Volatility12.82% 13.89%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.32 Prev Close15.27
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume765.26K Price15.55
Recom- SMA20-8.80% SMA5024.13% SMA20027.33% Volume246,868 Change1.83%
Jan-28-22 04:05PM  
Jan-26-22 12:36PM  
Jan-25-22 08:00PM  
Jan-19-22 03:01AM  
Jan-18-22 07:38AM  
Jan-12-22 07:28AM  
03:01AM  
Jan-11-22 03:01AM  
Jan-05-22 10:12AM  
09:12AM  
07:30AM  
03:01AM  
Dec-21-21 03:01AM  
Dec-14-21 03:01AM  
Dec-07-21 03:01AM  
Nov-30-21 03:01AM  
Nov-18-21 03:01AM  
Nov-15-21 06:26AM  
03:01AM  
Nov-11-21 03:01AM  
Nov-08-21 01:45PM  
03:42AM  
03:01AM  
Nov-05-21 05:06PM  
04:23PM  
02:57PM  
12:35PM  
12:24PM  
11:54AM  
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.